ITEM VIEW

Benefit v. risk when using chloroquine in patients with severe COVID-19 disease

dc.contributor.authorDecloedt, Eric H.en_ZA
dc.contributor.authorAllwood, Brian W.en_ZA
dc.contributor.authorParker, Arifaen_ZA
dc.contributor.authorKoegelenberg, Coenraad F. N.en_ZA
dc.contributor.authorBlockman, Marcen_ZA
dc.contributor.authorTaljaard, Jantjieen_ZA
dc.contributor.authorReuter, Helmuthen_ZA
dc.date.accessioned2020-04-15T08:18:56Z
dc.date.available2020-04-15T08:18:56Z
dc.date.issued2020-04-02
dc.identifier.citationDecloedt, E. H. et al. 2020. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease. South African Medical Journal, doi.org/10.7196/SAMJ.2020.v110i5.14761.
dc.identifier.issn2078-5135 (online)
dc.identifier.otherdoi.10.7196/SAMJ.2020.v110i5.14761
dc.identifier.urihttp://hdl.handle.net/10019.1/107693
dc.descriptionCITATION: Decloedt, E. H. et al. 2020. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease. South African Medical Journal, doi.org/10.7196/SAMJ.2020.v110i5.14761.
dc.descriptionThe original publication is available at http://www.samj.org.za
dc.description.abstractENGLISH ABSTRACT: Chloroquine (CQ) is widely advocated as treatment for coronavirus disease 2019 (COVID-19), including the president of the USA publicly supporting the use of hydroxychloroquine (HCQ) as a ‘game-changer’ on the social media platform Twitter. CQ and HCQ are structurally similar, with HCQ having an N-hydroxyl-ethyl side-chain in place of the N-diethyl group.[1] Currently only CQ is being marketed in South Africa. We encourage the development of curative directed therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using appropriate designed trials and regulatory oversight, and caution against the indiscriminate use of CQ or HCQ. Careful patient selection is essential, including assessing prognosis, anticipated benefit and potential harms prior to initiating CQ/HCQ therapy.en_ZA
dc.format.extent1 pageen_ZA
dc.language.isoen_ZAen_ZA
dc.publisherHealth & Medical Publishing Groupen_ZA
dc.subjectCOVID-19 (Disease) -- Treatmenten_ZA
dc.subjectChloroquineen_ZA
dc.subjectAntimalarialsen_ZA
dc.subjectEpidemicsen_ZA
dc.titleBenefit v. risk when using chloroquine in patients with severe COVID-19 diseaseen_ZA
dc.typeArticleen_ZA
dc.description.versionPreprint
dc.rights.holderAuthors retain copyrighten_ZA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW